||This article needs additional citations for verification. (May 2012)|
|Systematic (IUPAC) name|
|Licence data||US FDA:|
|Pregnancy cat.||B (US)|
|Legal status||POM (UK) ℞-only (US)|
partly hepatic (CYP2C19)
|Half-life||1 - 1.5 hours|
|Mol. mass||359.444 g/mol|
| (what is this?)
Rabeprazole // is an antiulcer drug in the class of proton pump inhibitors. It was developed by Eisai Co. and is marketed by Janssen-Cilag as rabeprazole sodium under the brand names AcipHex (//, referring to pH) in the US, Pariet in Europe, Brazil, Canada, Japan, Russia and Australia, and Razo, Parit and Orpro in India.
Indications and usage 
Short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or ulcerative gastroesophageal reflux disease (GERD); maintaining healing and reducing relapse rates of heartburn symptoms in patients with GERD; treatment of daytime and nighttime heartburn and other symptoms associated with GERD; long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome and in combination with amoxicillin and clarithromycin to eradicate Helicobacter pylori.
- Gastric ulcer (GU)
- Peptic ulcer disease (PUD)
- Maintenance of healing of erosive or ulcerative GERD
- Healing of erosive and ulcerative GERD
- Healing of duodenal ulcers.
- Treatment of symptomatic GERD
- Treatment of pathological hypersecretory conditions (Zollinger-Ellison syndrome)
- Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence
- hypersensitivity to rabeprazole, substituted benzimidazoles or any of components of its pharmaceutical forms.
- pregnancy: FDA Pregnancy Ratings: B
- lactation: Thomson Lactation Ratings: Infant risk cannot be ruled out.
Restriction of usage 
- acute hepatic failure
- pediatric use in patients under 18 years of age (there are insufficient data about safety and efficiency of rabeprazole in this group of patients)
Side effects 
- In clinical trials the most common side effect assessed as possibly or probably related to AcipHex was headache in 2.4% of patients vs 1.6% taking placebo.
- abdominal pains
- dry mouth
- increased or decreased appetite
- muscle or bone pain
- skin eruption
Antacid preparations such as rabeprazole by suppressing acid mediated break down of proteins, leads to an elevated risk of developing food or drug allergies. This happens due to undigested proteins then passing into the gastrointestinal tract where sensitisation occurs. It is unclear whether this risk occurs with only long-term use or with short-term use as well.
Drug interactions 
Rabeprazole decreases the concentration of ketoconazole in the plasma (in 33%), increases the concentration of digoxin (in 22%), and does not interact with liquid antacids. Rabeprazole is compatible with any medicine metabolized by the CYP450 (theophylline, warfarin, diazepam, phenytoin).
Studies in mice and rats indicated the symptoms of acute toxicity due to overdose included: hypoactivity, labored respiration, convulsion, diarrhea, tremor, and coma. A study in dogs indicated that a dose of 2000mg/kg was not lethal.
Formulations and brand names 
Rabeprazole as "CYRA" (Systopic Labs Pvt Ltd), "Elpizole" (Orchid Chemicals & Pharmaceuticals), "Elpizole -20" (Orchid Chemicals & Pharmaceuticals), Rablet (Lupin), Acigard (3D), AcipHex, Rabeloc, Pariet, Rabider (Duta Formulations) is supplied in:
- Tablet, enteric-coated; 10 mg
- Tablet, enteric-coated; 20 mg
Rabeprazole is sold under the brand names Acigard, Cyra, Rabium, Esoon, Rabemac, Rabiloz, Razo, Rabifast and Rablet in India, and Zechin in Pakistan.
||This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations. (May 2012)|
- Morii M, Takata H, Fujisaki H, Takeguchi N., The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor, Biochem. Pharmacol. 1990 Feb 15;39(4):661-7.
- Prakash A, Faulds D., Rabeprazole, Drugs. 1998 Feb;55(2):261-7; discussion 268.